Zeria Pharmaceutical Co., Ltd. 4559

TSE · Japan · Health Technology

¥1,902.00-49.00 (-2.51%)

Market open· Oct 2, 2026, 4:41 AM UTC· JPY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Zeria Pharmaceutical Co., Ltd. 4559

TSE · Japan · Health Technology

¥1,902.00-49.00 (-2.51%)

Market open· Oct 2, 2026, 4:41 AM UTC· JPY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-17.09% · 6MFull-screen chart

Open ¥1,938.00High ¥1,938.00Low ¥1,895.00Close ¥1,902.00Volume 172.40K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: ¥1,951.00
Day range: ¥1,895.00 – ¥1,938.00
52-week range: ¥1,878.00 – ¥2,434.00
Volume: 172.40K
Market cap: ¥82.60B
P/E (last fiscal year): 9.9
Dividend yield (annualized): 2.55%
Next earnings date: 2026-11-04
Avg. volume (1Y): 103.91K

Performance

1 week

-5.36%

1 month

-4.23%

3 months

-7.19%

6 months

-16.08%

Year to date

-7.34%

1 year

-2.66%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Japan
Exchange: TSE
Shares outstanding: 44.08M
Employees: 1,748
ISIN: JP3428850006
Beta: 0.27

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJan 19, 2026

Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Underactive Bladder Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, underactive bladder syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China].

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.